LBSP Favicon

MechPath uses AI to advance animal-free drug research at Leiden Bio Science Park

A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial […]

A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify patterns and make reliable predictions without relying on animal testing.

Key results so far:

  • Human cells used in lab models appear to retain a “disease memory,” continuing to respond as if they were still in the body, offering more realistic models for conditions like fibrosis.

  • The newly developed CELLS-PATH validation tools help lab-grown models gain approval faster, paving the way for wider adoption in drug research.

Read more here.

Related posts

Life Sciences Café June Edition

Life Sciences Café June Edition

Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech...